Key clinical point: Better viral suppression should reduce risk of transmission to newborn.
Major finding: Among patients enrolled in weeks 29-37, viral suppression was higher in the raltegravir group (93%) compared with the efavirenz group (71%).
Study details: Randomized, controlled trial (n = 408).
Disclosures: The National Institutes of Health funded the study. Glaxo/ViiV, Merck, and Bristol-Myers Squibb supplied study drugs. Dr. Mirochnick has received research funding from those companies.
Mark Mirochnick et al. CROI 2019, Abstract 39 LB.